CD169 Expression in Lymph Nodes is Associated with Increased Infiltration of CD8⁺ T Cells in Tumors: A Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies.

Study	Cancer	Follow-up	Number (year)	CD169 expression	CD169 detection	CD169 low/high	CD8 expression	CD8 detection	CD8 low/high
Kumamoto et al. [19]	GC (TNM (I–III/IV: 270/24)	144 months	294 (<70, ≥70)	LySMs in RLN; LN-met: Neg: 175; Pos: 119	IHC	CD169^+/CD68^+; <0.65, ≥0.65	Tumor	IHC	CD8^+/mm^2; <287, ≥287
Zhang et al. [20]	HCC (TNM (I–II/III–IV: 227/144)	96 months	375 (20–81)	Tumor	IHC, FACS	CD169^+/mm^2; <200, ≥200	Tumor	IHC, FACS	CD8^+/mm^2 <150, ≥150
Ohnishi et al. [14]	CRC (TNM (I–II/III–IV: 49/34)	100 months	83 (29–90)	RLN; LN-met: Neg: 55; Pos: 28	IHC	CD169^+/mm^2; <150, ≥150	Tumor	IHC	CD8^+/mm^2; <160, ≥160
Takeya et al. [21]	EPC; (PT+, PT−); (TNM (I/II/III/IV; 69/63/41/9)	140 months	182; (66.46)	LySMs in RLN; LN-met: Neg: 95; Pos: 87; (cancer cell free)	IHC	CD169 score; ≤4, >4	Tumor	IHC	CD8 score; 1; 2 or 3
Li et al. [22]	HCC; (TNM (I/II/III130/16/39); GC; (TNM (I/II/III8/25/99)	120 months	188 (13–76); 138 (28–78)	Tumor	IHC	CD169^+/mm^2; <200, ≥200	Intratumor; Nontumor	IHC	CD8^+/mm^2; <150, ≥150
Asano et al. [23]	BC (T1, T2: 22 T3, T4: 22)	140 months	44; (<70, ≥70)	RLN; LN-met: Neg: 38; Pos: 6	IHC	CD169 score 0–4, 5–6	Tumor	IHC	CD8^+/mm^2; <343, ≥343
Ohnishi et al. [15]	EC (TNM (I/II–IV: 41/38)	120 months	79 (<60, ≥60)	RLN; LN-met: Neg: 66; Pos: 13	IHC	CD169^+/mm^2; <350, ≥350	Tumor	IHC	CD8^+/mm^2; <120, ≥120
Saito et al. [16]	MM (TNM (I/II/III/IV 26/37/26/1)	100 months	95 (34–91)	RLN; LN-met: Neg: 61; Pos: 23	IHC	CD169^+/mm^2; <300, ≥300	Tumor	IHC	CD8 score 1; 2 or 3
Shiota et al. [24]	Breast cancer (TNM (I/II–III: 57/89)	160 months	146 (<55, ≥56)	RLN; LN-met: Neg: 92; Pos: 54	IHC	CD169^+/mm^2; <400, ≥400	Tumor	IHC	CD8^+/mm^2 <150, ≥150
Kawaguchi et al. [25]	OSCC (T1, T2 : 44 T3, T4 : 45)	70 months	89 (33–88)	RLN; LN-met: Neg: 27; Pos: 62	IHC	CD169 score 0–4, 4.5–6	Tumor	IHC	CD8^+/mm^2 <1,000, ≥1,000

TNM: tumor-node-metastasis; LN-met: lymph node-metastasis; Neg: negative; Pos: positive; GC: gastric cancer; HCC: hepatocellular carcinoma; CRC: colorectal carcinoma; EPC: esophageal cancer; BC: bladder cancer; EC: endometrial carcinoma; MM: malignant melanoma; OSCC: oral squamous cell carcinoma; LySMs: lymph node sinus macrophages; RLN: regional lymph nodes; IHC: immunohistochemistry; FACS: flow cytometry; PT: pretreatment.